Table 4 Prediction of absorption changes in oral antineoplastic drugs for which the food effects are unknown
Prediction | Generic name | Usage | logP | lnFaSSGF | lnFaSSIF | lnFeSSIF |
|---|---|---|---|---|---|---|
absorption increase (logP ≥4.34) | toremifene citrate | – | 6.73 | − 2.23 | −4.34 | −0.73 |
tamoxifen citrate | – | 6.64 | −2.11 | −4.20 | −0.58 | |
tretinoin | postprandial | 6.07 | −6.91 | −3.44 | −1.13 | |
mitotane | – | 6.06 | −6.91 | −4.42 | −1.06 | |
mepitiostane | – | 6.01 | −7.83 | −4.51 | −2.56 | |
tamibarotene | postprandial | 5.80 | −5.81 | −3.06 | −1.13 | |
cytarabine ocfosphate hydrate | postprandial | 4.56 | −4.02 | −5.81 | −5.81 | |
no prediction | medroxyprogesterone acetate | – | 3.94 | −5.30 | −4.27 | −2.59 |
estramustine phosphate sodium hydrate | – | 3.92 | −3.30 | −1.20 | −1.56 | |
flutamide | postprandial | 2.90 | −2.69 | − 2.15 | −1.72 | |
anastrozole | – | 2.67 | −2.90 | −3.54 | −1.48 | |
absorption invariant (logP < 1.59) | cyclophosphamide hydrate | – | 0.77 | 2.47 | 1.96 | 2.84 |
etoposide | – | 0.76 | −2.00 | −1.80 | −1.51 | |
sobuzoxane | – | 0.46 | −0.11 | −3.04 | −1.94 | |
tegafur | – | −0.12 | 1.35 | 1.49 | 2.28 | |
tegafur/gimeracil/oteracil potassium | postprandial | −0.12 | 1.35 | 1.49 | 2.28 | |
melphalan | – | −0.34 | 2.27 | 1.29 | 0.77 | |
mercaptopurine hydrate | – | −0.52 | 0.91 | −1.14 | −0.46 | |
fluorouracil | – | −0.81 | 1.49 | 1.66 | 2.67 | |
busulfan | – | −0.81 | 3.35 | 7.89 | 5.01 | |
doxifluridine | – | −1.08 | 2.50 | 3.57 | 3.36 | |
methotrexate | – | −1.11 | 3.02 | 1.06 | −1.86 | |
hydroxycarbamide | – | −1.66 | 3.90 | 3.74 | 3.12 | |
ubenimex | – | −1.67 | 3.33 | 2.26 | 1.72 |